Novo Nordisk consensus shifts after fresh analyst calls, shares hold near Copenhagen highs
23.06.2026 - 21:04:55 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:56.
Novo Nordisk (DK0062498333) remains in focus on the Nasdaq Copenhagen today as several research houses update their views on the Danish pharmaceutical group. The fresh calls refine the analyst consensus on the Novo Nordisk stock, which trades in the large-cap segment alongside peers such as Eli Lilly.
What recent analyst notes say
Berenberg recently lifted its price target for Novo Nordisk to 325 Danish kroner and reiterated a Buy rating, according to a 18 June note summarized by MarketScreener. MarketScreener analyst overview on Novo Nordisk The bank points to ongoing strong demand for GLP-1-based obesity and diabetes treatments as a central driver.
Deutsche Bank keeps a Hold rating with a 290 kroner target, reflecting a more cautious stance on valuation, as reported on 19 June in the same compilation. Deutsche Bank rating summary via MarketScreener Nordea Bank, by contrast, has issued a Buy recommendation, underlining Novo Nordisk’s pipeline and profitability profile.
Consensus picture on Novo Nordisk shares
The clustering of positive views from Berenberg and Nordea contrasts with Deutsche Bank’s Hold but keeps the overall stance on Novo Nordisk tilted toward Buy in many coverage lists. Reuters sector report on weight-loss drug makers Reuters highlights that the company, together with US rival Eli Lilly, dominates the fast-growing market for weight-loss medicines.
On Nasdaq Copenhagen, the B-shares traded around 304 to 306 kroner in recent sessions, according to exchange-based data, leaving them about one third above their 52-week low of 224.25 kroner reached in March 2026. FT market data on Novo Nordisk B shares That positioning reflects sustained expectations for earnings growth but also embeds the valuation concerns some analysts stress.
All news and analysis on the Novo Nordisk shares
Track the latest headlines, analyst opinions and price data for Novo Nordisk in one place.
How Novo Nordisk makes its money
Novo Nordisk generates the bulk of its revenue from diabetes and obesity care, with products such as Ozempic and Wegovy based on semaglutide, a GLP-1 receptor agonist. The group also sells insulin formulations and treatments for rare blood and endocrine disorders.
Where the Novo Nordisk stock trades today
The Novo Nordisk B shares (DK0062498333) traded on Nasdaq Copenhagen at about 304.60 Danish kroner on 2026-06-23, 15:30 local time, according to recent market data. This level leaves the shares roughly 36 percent above their 52-week low.
Key data on the Novo Nordisk shares
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3EU6F
- Ticker: NOVO B
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-23, 15:30): 304.60 DKK
- Market cap: around 1.02 trillion DKK (as of 2026-06-23)
- Sector / industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: OMX Copenhagen 25, STOXX Europe 50
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation before making investment decisions.
